Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Equity Ratio (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Equity Ratio for 7 consecutive years, with 0.43 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 501.24% year-over-year to 0.43, compared with a TTM value of 0.43 through Sep 2025, down 501.24%, and an annual FY2024 reading of 0.21, down 156.73% over the prior year.
  • Equity Ratio was 0.43 for Q3 2025 at Goldenwell Biotech, down from 0.35 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q3 2022 and bottomed at 0.43 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.41, with a median of 0.65 recorded in 2021.
  • The sharpest move saw Equity Ratio soared 30.61% in 2022, then tumbled 1909.98% in 2025.
  • Year by year, Equity Ratio stood at 0.65 in 2021, then grew by 24.01% to 0.81 in 2022, then plummeted by 54.24% to 0.37 in 2023, then plummeted by 156.73% to 0.21 in 2024, then tumbled by 104.17% to 0.43 in 2025.
  • Business Quant data shows Equity Ratio for GWLL at 0.43 in Q3 2025, 0.35 in Q2 2025, and 0.43 in Q1 2025.